plerixafor + granulocyte colony-stimulating factor + chemotherapy

This drug regimen is a **combination therapy** consisting of plerixafor, granulocyte colony-stimulating factor (G-CSF), and chemotherapy, primarily used for mobilizing hematopoietic stem cells (CD34+ cells) into the peripheral blood for collection, ahead of autologous stem cell transplantation in patients with lymphoma (both Hodgkin and non-Hodgkin) and multiple myeloma. **Plerixafor** is a small molecule CXCR4 antagonist that disrupts the interaction between the chemokine receptor CXCR4 and its ligand SDF-1α, thereby promoting the release of stem cells from the bone marrow into the bloodstream. **G-CSF** is a recombinant protein cytokine that stimulates neutrophil production and also mobilizes progenitor cells. **Chemotherapy** in this context (such as cyclophosphamide or fludarabine) is used to further induce stem cell mobilization by damaging hematopoietic stem cell niches and stimulating rebound progenitor cell release. The combination is used when conventional mobilization with G-CSF alone is insufficient. Plerixafor is generally administered subcutaneously, and G-CSF is typically administered subcutaneously or intravenously. The chemotherapy agent and its administration depend on local protocols. This combined approach has demonstrated efficacy in achieving adequate CD34+ cell collection for successful transplantation and is well tolerated, showing minimal serious non-hematologic toxicity[1][2][4].